The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Non-HDL Cholesterol and Triglycerides: Implications for Coronary Atheroma Progression and Clinical Events
Open accessAbstract
Objectives—: Non–high-density lipoprotein cholesterol (non-HDLC) levels reflect the full burden of cholesterol transported in atherogenic lipoproteins. Genetic studies suggest a causal association between elevated triglycerides (TGs)-rich lipoproteins and atherosclerosis. We evaluated associations between achieved non-HDLC and TG levels on changes in coronary atheroma volume. Approach and Results—: Data were analyzed from 9 clinical trials involving 4957 patients with coronary disease undergoing serial intravascular ultrasonography to assess changes in percent atheroma volume (ΔPAV) and were evaluated against on-treatment non-HDLC and TG levels. The effects of lower (<100 mg/dL) versus higher (≥100 mg/dL) achieved non-HDLC levels and lower (<200 mg/dL) versus higher (≥200 mg/dL) achieved TG levels were evaluated in populations with variable on-treatment low-density lipoprotein cholesterol (LDLC) </≥70 mg/dL and C-reactive protein </≥2 mg/L and in patients with or without diabetes mellitus. On-treatment non-HDLC levels linearly associated with ΔPAV. Overt PAV progression (ΔPAV>0) was associated with achieved TG levels >200 mg/dL, respectively. Lower on-treatment non-HDLC and TG levels associated with significant PAV regression compared with higher non-HDLC and TG levels across all levels of LDLC and C-reactive protein and irrespective of diabetic status ( P <0.001 across all comparisons). ΔPAV were more strongly influenced by changes in non-HDLC (β=0.62; P <0.001) compared with changes in LDLC (β=0.51; P <0.001). Kaplan–Meier sensitivity analyses demonstrated significantly greater major adverse cardiovascular event rates in those with higher versus lower non-HDLC and TG levels, with an earlier separation of the non-HDLC compared with the LDLC curve. Conclusions—: Achieved non-HDLC levels seem more closely associated with coronary atheroma progression than LDLC. Plaque progression associates with achieved TGs, but only above levels of 200 mg/dL. These observations support a more prominent role for non-HDLC (and possibly TG) lowering in combating residual cardiovascular risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Elevated levels of TRLs and remnant lipoproteins contribute directly to atherosclerosis by promoting endothelial dysfunction, inflammation, and foam cell formation [8, 9].”
From Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies (2026) · cites this paper as [9]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Genetic studies and epidemiologic data increasingly implicate remnant lipoproteins as causal contributors to atherogenesis, providing a strong mechanistic and clinical rationale for targeted intervention [8–12].”
From Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies (2026) · cites this paper as [9]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.002 · Cited by 3,845
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837 · cited 1×
“However, clinical trials testing the efficacy of TG-lowering strategies have largely been negative.(26,27) This may be in part”
BackgroundMajor lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Nissen, S. E., Tuzcu, E. M., Schoenhagen, P., Brown, B. G., Ganz, P., Vogel, R. A., Crowe, T., Howard, G., Cooper, C. J., Brodie, B. R., et al. (2004) · JAMA · doi:10.1001/jama.291.9.1071 · Cited by 2,361
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Remnant Cholesterol, Not LDL Cholesterol, Is Associated With Incident Cardiovascular Disease
Castañer, O., Pintó, X., Subirana, I., Amor, A. J., Ros, E., Hernáez, Á., Martínez-González, M. Á., Corella, D., Salas-Salvadó, J., Estruch, R., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.10.008 · Cited by 540
“Our results confirmed previous evidence on the causal role of triglycerides in CVD (7,8,10,26).”
ResultHypertriglyceridaemia and risk of coronary artery disease
Reiner, Ž. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.31 · Cited by 390
Kwaifa, I. K., Bahari, H., Yong, Y. K., & Noor, S. M. (2020) · Biomolecules · doi:10.3390/biom10020291 · Cited by 345
“Other related biomarkers include: growth differentiation factor-15 (GDF15), myeloid-related proteins 8/14, pentraxin 3, and lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), which were identified as surrogate markers of atherosclerosis associated with cardiovascular diseases during obesity [45,46], whil…”
BackgroundHypertriglyceridemia and atherosclerosis
Peng, J., Luo, F., Ruan, G., Peng, R., & Li, X. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0625-0 · Cited by 268
“[32] analyzed the data from 9 clinical trials involving 4957 patients with coronary disease undergoing serial intravascular ultrasonography to measure coronary atheroma volume and investigated the relationship between achieved non-HDLC and TG levels with coronary atheroma progression regression rates in a large cohort…”
MethodNicholls, S. J., Lincoff, A. M., Bash, D., Ballantyne, C. M., Barter, P. J., Davidson, M. H., Kastelein, J. J. P., Koenig, W., McGuire, D. K., Mozaffarian, D., et al. (2018) · Clinical Cardiology · doi:10.1002/clc.23055 · Cited by 167
Self-citationRemnant cholesterol and risk of ischemic stroke in 112,512 individuals from the general population
Varbo, A., & Nordestgaard, B. G. (2019) · Annals of Neurology · doi:10.1002/ana.25432 · Cited by 145
Addressing dyslipidemic risk beyond LDL-cholesterol
Tall, A. R., Thomas, D. G., Gonzalez-Cabodevilla, A. G., & Goldberg, I. J. (2022) · Journal of Clinical Investigation · doi:10.1172/jci148559 · Cited by 150
“Moreover, marked reductions in non-HDL cholesterol and to a lesser extent TGs associate with plaque regression as determined by intravascular ultrasound of coronary arteries (19).”
BackgroundVarbo, A., & Nordestgaard, B. G. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000429 · Cited by 135
Varbo, A., & Nordestgaard, B. G. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.308305 · Cited by 147
Fruchart, J.-C., Santos, R. D., Aguilar-Salinas, C., Aikawa, M., Al Rasadi, K., Amarenco, P., Barter, P. J., Ceska, R., Corsini, A., Després, J.-P., et al. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0864-7 · Cited by 140
Vulnerable Plaque, Characteristics, Detection, and Potential Therapies
Hafiane, A. (2019) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd6030026 · Cited by 130
“Moderate or intensive statin therapy reduces LDL-C [118], promotes atheroma stabilization [45], and induces coronary plaque volume regression [11,117,152].”
BackgroundMa, Q., Fan, Q., Han, X., Dong, Z., Xu, J., Bai, J., Tao, W., Sun, D., & Wang, C. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.11.064 · Cited by 112
Elshazly, M. B., Mani, P., Nissen, S., Brennan, D. M., Clark, D., Martin, S., Jones, S. R., Quispe, R., Donnellan, E., Nicholls, S. J., et al. (2020) · European Journal of Preventive Cardiology · doi:10.1177/2047487319887578 · Cited by 103
Self-citationPathophysiology of cardiovascular disease in diabetes mellitus
Rodriguez‐Araujo, G., & Nakagami, H. (2018) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000141 · Cited by 100
Ray, K. K., Corral, P., Morales, E., & Nicholls, S. J. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31950-6 · Cited by 94
Self-citationWu, B., Pan, Y., Li, Z., Wang, J., Ji, S., Zhao, F., Chang, X., Qu, Y., Zhu, Y., Xie, L., et al. (2023) · Environment International · doi:10.1016/j.envint.2023.107779 · Cited by 89
Gragnano, F., & Calabrò, P. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.01.012 · Cited by 89
Cholesterol Remnants, Triglyceride-Rich Lipoproteins and Cardiovascular Risk
Baratta, F., Cocomello, N., Coronati, M., Ferro, D., Pastori, D., Angelico, F., & Ben, M. D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054268 · Cited by 89
The Complex Interplay between Lipids, Immune System and Interleukins in Cardio-Metabolic Diseases
Bernardi, S., Marcuzzi, A., Piscianz, E., Tommasini, A., & Fabris, B. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19124058 · Cited by 71
“Nevertheless, lowering triglyceride levels <200 mg/dL ameliorates atherosclerotic disease in patients with well-controlled LDL [67].”
BackgroundGeneroso, G., Janovsky, C. C. P. S., & Bittencourt, M. S. (2019) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000468 · Cited by 72
Yu, D., Wang, Z., Zhang, X., Qu, B., Cai, Y., Ma, S., Zhao, Z., & Simmons, D. S. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab533 · Cited by 64
Lin, A., Nerlekar, N., Rajagopalan, A., Yuvaraj, J., Modi, R., Mirzaee, S., Munnur, R. K., Seckington, M., Doery, J. C. G., SENEVIRATNE, S. K., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.02.019 · Cited by 65
Self-citationBjörnsson, E., Þorleifsson, G., Helgadóttir, A., Guðnason, Þ., Guðbjartsson, T., Andersen, K. K., Grétarsdóttir, S., Ólafsson, Í., Tragante, V., Ólafsson, Ó., et al. (2019) · JAMA Cardiology · doi:10.1001/jamacardio.2019.2946 · Cited by 59
Spigoni, V., Aldigeri, R., Antonini, M., Micheli, M., Fantuzzi, F., Fratter, A., Pellizzato, M., Derlindati, E., Zavaroni, I., Bonadonna, R. C., et al. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071498 · Cited by 60
The Impact of the Blood Lipids Levels on Arterial Stiffness
Baba, M., Mariș, M. I., Jianu, D., Luca, C. T., Stoian, D. L., & Mozos, I. M. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10030127 · Cited by 56
Cho, D. I., Ahn, M. J., Cho, H. H., Cho, M., Jun, J. H., Kang, B. G., Lim, S. Y., Yoo, S. J., Kim, M. R., Kim, H.-S., et al. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-00937-x · Cited by 55
Update on the laboratory investigation of dyslipidemias
Ramasamy, I. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.01.015 · Cited by 50
HDL-C and non-HDL-C levels are associated with anthropometric and biochemical parameters
Barbalho, S. M., Tofano, R. J., de Oliveira, M. B., Quesada, K. R., Barion, M. R., Akuri, M. C., Oshiiwa, M., & Bechara, M. D. (2019) · Jornal Vascular Brasileiro · doi:10.1590/1677-5449.180109 · Cited by 48
Zhan, B., Huang, X. B., Wang, J., Qin, X., Zhang, J., Cao, J., Song, Y., Liu, L., Li, P., Yang, R., et al. (2019) · Angiology · doi:10.1177/0003319718823341 · Cited by 48
Björnson, E., Packard, C. J., Adiels, M., Andersson, L., Matikainen, N., Söderlund, S., Kahri, J., Hakkarainen, A., Lundbom, N., Lundbom, J., et al. (2020) · Journal of Internal Medicine · doi:10.1111/joim.13017 · Cited by 46
Sekimoto, T., Koba, S., Mori, H., Sakai, R., Arai, T., Yokota, Y., Sato, S., Tanaka, H., Masaki, R., Oishi, Y., et al. (2021) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.60152 · Cited by 46
Spannella, F., Giulietti, F., Pentima, C. D., & Sarzani, R. (2019) · Advances in Therapy · doi:10.1007/s12325-019-00941-6 · Cited by 46
Elkhatib, M. A. W., Mroueh, A., Rafeh, R. W., Sleiman, F., Fouad, H. H., Saad, E. I., Fouda, M. A., Elgaddar, O., Issa, K., Eid, A. H., et al. (2019) · Translational research · doi:10.1016/j.trsl.2019.07.009 · Cited by 41
Bashir, B., Schofield, J., Downie, P., France, M., Ashcroft, D. M., Wright, A. K., Romeo, S., Gouni-Berthold, I., Maan, A., Durrington, P. N., et al. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1389106 · Cited by 40
“…LDL-C of 1.8 mmol/L (70 mg/dl), with a further 50% – 55% reduction after treatment, 20% did not have regression in atheroma volume despite achieving very low LDL-C (86), thereby suggesting a role of TG-rich lipoproteins and other factors (Figure 1) in atheroma development and progression (87).”
BackgroundInfluentialAssociation between vitamin D status and metabolic syndrome risk factors
Barbalho, S. M., Tofano, R. J., de Campos, A. L., Rodrigues, A. S., Quesada, K. R., Bechara, M. D., Goulart, R. D. Á., & Oshiiwa, M. (2018) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2018.03.011 · Cited by 40
Apolipoprotein profiling as a personalized approach to the diagnosis and treatment of dyslipidaemia
Renee Ruhaak, L., van der Laarse, A., & Cobbaert, C. M. (2019) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1177/0004563219827620 · Cited by 38
Suzuki, K., Oikawa, T., Nochioka, K., Miura, M., Kasahara, S., Sato, M., Aoyanagi, H., Shiroto, T., Takahashi, J. A., Miyata, S., et al. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.312336 · Cited by 35
Shen, Y. H., Chen, S., Dai, Y., Wang, X. Q., Zhang, R., YANG, Z. K., Hu, J., Lu, L., Ding, F. H., & Shen, W. F. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0888-z · Cited by 32
Ascaso, J. F., Millán, J., Hernández‐Mijares, A., Blasco, M., Brea, Á., Rodríguez, Á. D., Mantilla, T., Pedro‐Botet, J., & Pintó, X. (2017) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2016.11.001 · Cited by 31
Müller‐Wieland, D., Leiter, L. A., Cariou, B., Letierce, A., Colhoun, H. M., Prato, S. D., Henry, R. R., Tinahones, F. J., Aurand, L. A., Maroni, J. M., et al. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0552-4 · Cited by 30
Wu, X., Gao, Y., Wang, M., Peng, H., Zhang, D., Qin, B., Pan, L., & Zhu, G. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-00992-4 · Cited by 28
“even more strongly linked to the development of coronary atheroma [27].”
BackgroundHypertriglyceridemia in Diabetes Mellitus: Implications for Pediatric Care
Hartz, J. C., de Ferranti, S. D., & Gidding, S. S. (2018) · Journal of the Endocrine Society · doi:10.1210/js.2018-00079 · Cited by 29
da Silva, P. M., Duarte, J. S., HAFE, P. V., Gil, V. M., de Oliveira, J. N., & de Sousa, G. (2018) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2018.04.001 · Cited by 26
Mardi, P., Abdi, F., Ehsani, A., Seif, E., Djalalinia, S., Heshmati, J., Shahrestanaki, E., Gorabi, A. M., & Qorbani, M. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.957136 · Cited by 25
Cardiac biomarkers in diabetes mellitus: New dawn for risk stratification?
Berezin, A. Е. (2016) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2016.12.032 · Cited by 24
Bonfiglio, C., Leone, C. M., Silveira, L. V. D. A., Guerra, R., Misciagna, G., Caruso, M. G., Bruno, I., Buongiorno, C., Campanella, A., Guerra, V. M. B., et al. (2020) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2020.07.002 · Cited by 24
Viktorínová, A., Malickova, D., Sviteková, K., Choudhury, S., & Krizko, M. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108858 · Cited by 24
Park, H., Arsanjani, R., Hong, S., Yi, J., & Yi, S. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad330 · Cited by 25
Benitez‐Amaro, A., Pallara, C., Nasarre, L., Rivas-Urbina, A., Benı́tez, S., Vea, À., Bornachea, O., de Gonzalo‐Calvo, D., Serra-Mir, G., Villegas, S., et al. (2019) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2019.05.003 · Cited by 23
Is it possible to predict the complexity of peripheral artery disease with atherogenic index?
Engin, M., Aydın, C., & Güvenç, O. (2020) · Vascular · doi:10.1177/1708538120923531 · Cited by 23
Kitagami, M., Yasuda, R., Toma, N., Shiba, M., Nampei, M., Yamamoto, Y., Nakatsuka, Y., Sakaida, H., & Suzuki, H. (2017) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2017.04.010 · Cited by 21
Zhao, Q., Zhang, T., Cheng, Y., Ma, Y., Xu, Y.-K., Yang, J., & Zhou, Y.-J. (2020) · Lipids in Health and Disease · doi:10.1186/s12944-020-01355-y · Cited by 19
Triglyceride-Rich Lipoproteins and Novel Targets for Anti-atherosclerotic Therapy
Reiner, Ž. (2018) · Korean Circulation Journal · doi:10.4070/kcj.2018.0343 · Cited by 19
Wang, Y., Song, Q., Cheng, Y., Wei, C., Ye, C., Liu, J., Wu, B., & Liu, M. (2020) · BMC Neurology · doi:10.1186/s12883-020-1615-9 · Cited by 19
β-Aminoisobutyric Acid Suppresses Atherosclerosis in Apolipoprotein E-Knockout Mice
Shimba, Y., Katayama, K., Miyoshi, N., Ikeda, M., Morita, A., & Miura, S. (2020) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b20-00078 · Cited by 18
Gómez-Delgado, F., Alcala-Diaz, J. F., Leon‐Acuña, A., López-Moreno, J., Delgado‐Lista, J., Gomez‐Marin, B., Roncero‐Ramos, I., Yubero‐Serrano, E. M., Rangel-Zúñiga, O. A., Vals‐Delgado, C., et al. (2019) · European Journal of Clinical Investigation · doi:10.1111/eci.13146 · Cited by 18
Chapman, M. J., Orsoni, A., Robillard, P., Thérond, P., & Giral, P. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.02.001 · Cited by 18
Endothelial Dysfunction in Type 2 Diabetes: Targeting Inflammation
Sena, C. M., Carrilho, F., & Seiça, R. M. F. (2018) · InTech eBooks · doi:10.5772/intechopen.76994 · Cited by 21
Dansinger, M. L., Williams, P. T., Superko, H. R., & Schaefer, E. J. (2019) · Lipids in Health and Disease · doi:10.1186/s12944-019-1094-4 · Cited by 17
Hosseinpour‐Niazi, S., Afaghi, S., Hadaegh, P., Mahdavi, M., Farhadnejad, H., Tohidi, M., Mirmiran, P., Azizi, F., & Hadaegh, F. (2023) · Journal of Diabetes Investigation · doi:10.1111/jdi.14101 · Cited by 16
“It has been reported that among individuals with prior coronary artery disease with LDL-C less than 70 mg/dL, lowering triglyceride to less than 200 mg/dL was associated with a lessening of coronary atheroma progression and a lowering of the residual risk of cardiovascular disease events 37 .”
BackgroundRecent Advances in the Development of Cardiovascular Biomarkers
Satoh, K., & Shimokawa, H. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.310226 · Cited by 15
“They concluded that their findings provide mechanistic support for the possible roles of non-HDL cholesterol and triglycerides to more definitively emerge as future therapeutic targets, especially in statin-treated patients requiring secondary prevention.(89) Kockx et al(90) reported on the LDLr (LDL receptor)–”
BackgroundDo triglyceride-lowering drugs decrease risk of cardiovascular disease?
Maki, K. C., & Dicklin, M. R. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000424 · Cited by 14
Vallejo‐Vaz, A. J., Leiter, L. A., Prato, S. D., Taskinen, M., Müller‐Wieland, D., Bujas‐Bobanovic, M., Letierce, A., Mandel, J., Samuel, R., & Ray, K. K. (2020) · European Journal of Preventive Cardiology · doi:10.1177/2047487320905185 · Cited by 14
KEECH, A. C., & Jenkins, A. J. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000465 · Cited by 14
“Clinically available drugs are italicized: HMG CoA reductase inhibition via HMG CoA reductase inhibitors (statins); [1] intestinal cholesterol absorption inhibition via inhibitor of Niemann Pick Like protein-1 transporter, ezetimibe; [2] binding and excretion of cholesterol rich bile acids by bile acid binding resins;…”
MethodAnti-atherogenic properties of vitamin E, aspirin, and their combination
Chai, S. C., Foley, E., & Arjmandi, B. H. (2018) · PLoS ONE · doi:10.1371/journal.pone.0206315 · Cited by 14
Impact of triglyceride levels on plaque characteristics in patients with coronary artery disease
Asakura, K., Minami, Y., Kinoshita, D., Katamine, M., Kato, A., Katsura, A., Sato, T., Muramatsu, Y., Hashimoto, T., Kameda, R., et al. (2021) · International Journal of Cardiology · doi:10.1016/j.ijcard.2021.12.008 · Cited by 14
Umishio, W., Ikaga, T., Kario, K., Fujino, Y., Suzuki, M., Hoshi, T., Ando, S., Yoshimura, T., Yoshino, H., & Murakami, S. (2022) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.63494 · Cited by 14
Aydınyılmaz, F., Özbeyaz, N. B., Gulıyev, İ., Algül, E., Şahan, H. F., & Kalkan, K. (2023) · Angiology · doi:10.1177/00033197231185204 · Cited by 13
“20 Also, TG concentrations are directly related to residual lipoproteins that are highly atherogenic and have a high risk of penetrating the arterial wall.”
Welty, F. K., Hariri, E. H., Asbeutah, A. A., Daher, R., Amangurbanova, M., Chedid, G., Elajami, T. K., Alfaddagh, A., & Malik, A. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.123.030071 · Cited by 13
Jun, J. E., Jeong, I., Yu, J. M., Kim, S. R., Lee, I. K., Han, K. A., Choi, S. H., Kim, S., Park, H. K., Mok, J., et al. (2019) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2018.0265 · Cited by 12
Colivicchi, F., Fusco, S. A. D., Arca, M., Leggio, M., Caldarola, P., Murrone, A., Valente, S., Urbinati, S., Roncon, L., Amodeo, V., et al. (2021) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001175 · Cited by 13
Islam, M. N., Mishra, V. K., Munalisa, R., Parveen, F., Ali, S. F., Akter, K., Ahmed, T., Ho, T., & Huang, C. (2024) · Molecular & Cellular Toxicology · doi:10.1007/s13273-023-00424-4 · Cited by 11
“…and CVDs, there are some other delegate inflammatory markers, such as GDF-15 (growth differentiation factor-15), myeloid-related protein 8/14, pentraxin3, galectin-3 and LOX-1, these would be better called as dyslipidemia markers (Krintus et al. 2014; Papapanagiotou et al. 2015; Puri et al. 2016).”
Ascaso, J. F., Millán, J., Hernández‐Mijares, A., Blasco, M., Brea, Á., Rodríguez, Á. D., Mantilla, T., Pedro‐Botet, J., & Pintó, X. (2017) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2016.11.001 · Cited by 11
Wang, S., Wang, S., Yu, X. M., Zeng, J., Li, H., Yang, R., Chen, W., & Dong, J. (2019) · Chemical Engineering Journal · doi:10.1016/j.cej.2019.123465 · Cited by 11
Relationship between remnant cholesterol and short‐term prognosis in acute ischemic stroke patients
Tan, Z., Zhang, Q., Liu, Q., Meng, X., Wu, W., Wang, L., & Wu, J. (2024) · Brain and Behavior · doi:10.1002/brb3.3537 · Cited by 10
Yin, D., Wang, M., Liu, X., Pan, W., Ren, Y., & Liu, J. (2023) · The International Journal of Cardiovascular Imaging · doi:10.1007/s10554-023-02932-9 · Cited by 9
“Furthermore, an IVUS study demonstrated that coronary plaque volume changes increased with the increase of serum TG levels [29].”
BackgroundDiabetes mellitus and heart disease
Chandrasekaran, P., & Weiskirchen, R. (2024) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2024.15 · Cited by 10
Ascaso, J. F., Millán, J., Hernández‐Mijares, A., Blasco, M., Brea, Á., Díaz, Á., Pedro‐Botet, J., & Pintó, X. (2020) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2020.05.002 · Cited by 10
“Estos efectos son dependien-tes de las concentraciones basales 11 y vienen recogidos en la tabla 3 26 .”
BackgroundWang, S., Tu, J., & Pan, Y. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s232343 · Cited by 9
New Approaches to Lipoproteins for the Prevention of Cardiovascular Events
Fujino, M., Giovanni, G. D., & Nicholls, S. J. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv22031 · Cited by 8
“Hypertriglyceridemia contributes to residual risk, even when low LDL-C levels are achieved through intensive statin therapy 60) .”
Self-citationLipoprotein cholesterol ratios and cardiovascular disease risk in US adults: a cross-sectional study
Yang, X., Chen, Q., Zhang, Q., & Yu, Z. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1529223 · Cited by 10
Non-HDL Cholesterol and Atherosclerotic Cardiovascular Disease.
Puri, R., Mehta, V., Iyengar, S. S., Narasingan, S. N., Duell, P. B., Sattur, G. B., Vijayaraghavan, K., Mohan, J. C., Wangnoo, S. K., Dalal, J. J., et al. (2020) · PubMed · Cited by 7
Self-citationBenitez‐Amaro, A., Pallara, C., Nasarre, L., Ferreira, R. C. S., de Gonzalo‐Calvo, D., Prades, R., Tarragó, T., & Llorente‐Cortés, V. (2020) · Advanced Therapeutics · doi:10.1002/adtp.202000037 · Cited by 8
Nkambule, B. B., Chan, M. V., Lachapelle, A., Grech, J., Thibord, F., Chen, M., & Johnson, A. D. (2023) · Thrombosis Research · doi:10.1016/j.thromres.2023.03.013 · Cited by 8
Azam, M., Hidayati, F. N., Fibriana, A. I., Bahrudin, U., & Aljunid, S. M. (2023) · Jurnal Kesehatan Masyarakat · doi:10.15294/kemas.v19i1.40548 · Cited by 8
Yamashita, M., Iwata, A., Kato, Y., Futami, M., Imaizumi, S., Kuwano, T., Ike, A., Sugihara, M., Nishikawa, H., Zhang, B., et al. (2018) · Heart and Vessels · doi:10.1007/s00380-018-1173-x · Cited by 8
“reported that an increase in TG levels was significantly associated with coronary atheroma progression as evaluated by IVUS [27].”
BackgroundAscaso, J. F., Millán, J., Hernández‐Mijares, A., Blasco, M., Brea, Á., Rodríguez, Á. D., Pedro‐Botet, J., & Pintó, X. (2020) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2019.11.004 · Cited by 10
Dirajlal‐Fargo, S., Jacobson, D. L., Yu, W., Mirza, A., Geffner, M. E., McComsey, G. A., Jao, J. K., & (PHACS), F. T. P. H. C. S. (2023) · HIV Medicine · doi:10.1111/hiv.13566 · Cited by 7
Wang, L., Han, Y. Y., Cao, C., Hu, H., & Li, H. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1303336 · Cited by 9
“Non-HDL-c encompasses all cholesterol with atherogenic potential in the bloodstream, and elevated levels of non-HDL-c have been linked to damage in vascular endothelial function (54, 55).”
BackgroundKataoka, Y., Kitahara, S., Funabashi, S., Makino, H., Matsubara, M., Matsuo, M., Omura‐Ohata, Y., Koezuka, R., Tochiya, M., Tamanaha, T., et al. (2024) · Atherosclerosis Plus · doi:10.1016/j.athplu.2024.03.001 · Cited by 7
“Observational and intravascular imaging studies have consistently reported the association of triglyceride-rich lipoproteins with atherosclerosis [29 – 32], suggesting they are a potential therapeutic target.”
BackgroundSelf-citationEvsen, A., Aktan, A., Altunova, M., & Özbek, M. (2024) · Vascular · doi:10.1177/17085381241260203 · Cited by 7
“16 In the study conducted by Salazar et al., it was demonstrated that the TG/HDL-C ratio predicts the extent of atherosclerosis more sensitively compared to a single blood lipid parameter.”
Triglycerides and the Risk of Atherosclerotic Cardiovascular Events Across Different Risk Categories
Mizuta, H., Ishii, M., Ikebe, S., Otsuka, Y., Yamanouchi, Y., Nakamura, T., & Tsujita, K. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.65334 · Cited by 8
“Previous reports have shown that in patients receiving secondary prevention on statin therapy for LDL-C management, TG levels ＞ 200 mg/dL was associated with an increased presence of coronary artery plaques 40) .”
Cardiovascular Risk Factors and Markers
Thiriet, M. (2018) · Biomathematical and biomechanical modeling of the circulatory and ventilatory systems · doi:10.1007/978-3-319-89315-0_2 · Cited by 8
Targeting triglycerides to lower residual cardiovascular risk
Bubb, K. J., Nelson, A. J., & Nicholls, S. J. (2022) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2022.2058489 · Cited by 8
“of cardiovascular events in the statin trials [22].”
BackgroundSelf-citationSreenivas Reddy, S., Raghavendra Rao, K., Kashyap, J. R., Kadiyala, V., Kumar, S., Dash, D., Uppal, L., Kaur, J., Kaur, M., Reddy, H., et al. (2024) · Indian Heart Journal · doi:10.1016/j.ihj.2024.10.004 · Cited by 7
Cardiovascular Immunotherapy and the Role of Imaging
Zupančič, E., Fayad, Z. A., & Mulder, W. J. M. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.309227 · Cited by 6
“adverse cardiovascular events, that is, myocardial infarctions or stroke, within the first 5 years.(30,34) Consistent with this find-”
Backgroundda Silva, P. M., Duarte, J. S., HAFE, P. V., Gil, V. M., de Oliveira, J. N., & de Sousa, G. (2018) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2017.07.013 · Cited by 6
Triglycerides and T Cells in Cardiovascular Risk
Reilly, N. A., Mulder, J. W. C. M., Dekkers, K. F., Kuipers, T. B., der Zee, L. C. V. V., Mulder, M. T., van Lennep, J. E. R., Jukema, J. W., & Heijmans, B. T. (2025) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2025.101359 · Cited by 5
Altunova, M., Karakayalı, M., Karakan, C. Y., Karakurt, S. T., Demirci, G., Aslan, S., Güler, A., Evsen, A., & Ertürk, M. (2023) · Vascular · doi:10.1177/17085381231193494 · Cited by 5
“18 Unlike TG, HDL-C has effects that inhibit the atherosclerotic process mainly by providing cholesterol transport from macrophages in the vascular wall toward the liver.”
BackgroundAsakura, K., Minami, Y., Nagata, T., Katamine, M., Muramatsu, Y., Kinoshita, D., & Ako, J. (2023) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-023-02888-6 · Cited by 5
Metadata
- Authors
- Puri, R., Nissen, S. E., Shao, M., Elshazly, M. B., Kataoka, Y., Kapadia, S. R., Tuzcu, E. M., & Nicholls, S. J.
- Affiliations
- Cleveland Clinic (US)
- ORCID
- Venue
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Published
- 2016-11
- Volume
- 36
- Issue
- 11
- Pages
- 2220-2228
- ISSN
- 1079-5642 (ISSN-L)
- 1524-4636
- OpenAlex
- W2509381650
- Cited by
- 143
- References
- 46
- Citations by year
- 2026: 7 · 2025: 4 · 2024: 17 · 2023: 18 · 2022: 8 · 2021: 11 · 2020: 17 · 2019: 24 · 2018: 20 · 2017: 14 · 2016: 3
- FWCI
- 22.51
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Arteriosclerosis Thrombosis and Vascular Biology (publishedVersion)
- PubMed (publishedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Funders
- Eli Lilly and Company
- Pfizer
- Sanofi
- Cleveland Clinic
- InfraRedx
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Keywords
- non-HDL cholesterol, triglycerides, atherosclerosis progression, LDL cholesterol, triglyceride-rich lipoproteins, residual cardiovascular risk, major adverse cardiovascular events, intravascular ultrasound, coronary artery disease, diabetes mellitus, C-reactive protein
- MeSH terms
- Aged, Hypolipidemic Agents, Cholesterol, Clinical Trials as Topic, Coronary Artery Disease, Coronary Vessels, Female, Humans, Male, Middle Aged, Predictive Value of Tests, Risk Factors, Time Factors, Triglycerides, Biomarkers, Multivariate Analysis, Linear Models, Treatment Outcome, Ultrasonography, Interventional, Disease Progression, Kaplan-Meier Estimate, Plaque, Atherosclerotic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
